AstraZeneca Announces Approval Of Koselugo In Canada

Health Canada approved AstraZeneca Rare Disease's Koselugo (Alexion) for adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The approval is a positive regulatory milestone that modestly de-risks AstraZeneca's rare-disease franchise and could add incremental revenue in a niche patient population, though commercial impact is likely limited by the small addressable market.

Analysis

Health Canada approved AstraZeneca Rare Disease's Koselugo (Alexion) for adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The approval is a positive regulatory milestone that modestly de-risks AstraZeneca's rare-disease franchise and could add incremental revenue in a niche patient population, though commercial impact is likely limited by the small addressable market.